Call 408.493.1800 | Fax 408.493.1801 | Toll Free 800.891.9699 (US Only) | Email: [email protected]

New

Anti-TNFSF11 (Denosumab), Human IgG2 Antibody

The biosimilar is a human monoclonal antibody that targets RANKL and inhibits the binding to its receptor RANK, thus reducing bone resorption and increasing bone mass and strength. The original drug received FDA approval to treat osteoporosis
Catalog #: A2150
$455.00

Product Details

Cat # +Size A2150-100
Size 100 μg
Antibody Target TNFSF11
Alternate Name AMG-162, AMG162, CD254, ODF, OPGL, sOdf, OPTB2, RANKL, TNLG6B, TRANCE, hRANKL2
Host Recombinant
Antibody Type Monoclonal
Isotype IgG2, kappa
Immunogen Human TNFSF11
Accession # DB06643
Appearance Colorless liquid
Concentration 1 mg/ml
Formulation In PBS, pH 7.5
Purification Protein A purified
Species Reactivity Human
Handling The antibody solution should be gently mixed before use.
Storage Conditions -80°C
Shipping Conditions Gel Pack
USAGE For Research Use Only! Not For Use in Humans.

Details

The research-grade biosimilar is a fully human IgG2 monoclonal antibody that specifically targets receptor activator of nuclear factor kappa-B ligand (RANKL), a protein that plays a key role in the formation, function, and survival of osteoclasts. RANKL belongs to the TNF superfamily of ligands. Interaction with the receptor (RANK) expressed on pre-osteoclast and mature osteoclast cells results in the activation, migration, differentiation, and fusion of hematopoietic cells of osteoclast lineage, and promotes bone resorption. By preventing the RANKL-RANK interaction, the antibody inhibits bone resorption and increases bone mass density and strength, thus decreasing the risk of hip, vertebral, and non-vertebral fractures. The original drug received approval from the FDA for the treatment of osteoporosis in postmenopausal women, and to treat patients with bone metastases


Why buy BioVision Products?
Innovation
Affordability
Global Presence
Technical Support
BioVision aims to provide our customers innovative tools for accelerating drug discovery and biological research. BioVision offers >8,000 products including the most comprehensive array of assay kits for key targets in Metabolic pathways.
BioVision is committed to providing the highest quality products at a competitive price.
We have a broad network of global distributors who are ready to address your research needs and ensure fast delivery.
Our highly trained Technical Support team provides comprehensive product support and is dedicated to resolving your issues quickly and efficiently.